{"id":2988,"date":"2024-02-01T17:18:09","date_gmt":"2024-02-01T16:18:09","guid":{"rendered":"https:\/\/invivo.partners\/?p=2988"},"modified":"2024-02-01T17:19:22","modified_gmt":"2024-02-01T16:19:22","slug":"onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo","status":"publish","type":"post","link":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/","title":{"rendered":"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-2989 alignleft\" src=\"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-228x300.jpeg\" alt=\"\" width=\"228\" height=\"300\" srcset=\"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-228x300.jpeg 228w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-779x1024.jpeg 779w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-768x1009.jpeg 768w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-1169x1536.jpeg 1169w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-142x187.jpeg 142w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-1170x1537.jpeg 1170w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843.jpeg 1506w\" sizes=\"auto, (max-width: 228px) 100vw, 228px\" \/><\/p>\n<ul>\n<li><strong>El Dr. Theoharis ha ocupado puestos clave en varias empresas biotecnol\u00f3gicas y farmac\u00e9uticas de renombre y aporta m\u00e1s de veinte a\u00f1os de experiencia en el campo de la terapia celular y g\u00e9nica, el desarrollo empresarial y la gesti\u00f3n de programas.<\/strong><\/li>\n<li><strong>Se incorpora a la empresa para dirigirla hacia su siguiente fase de crecimiento, forjando nuevas alianzas y centr\u00e1ndose en \u00e1reas como la fabricaci\u00f3n, el reclutamiento de pacientes y el acceso al mercado. <\/strong><\/li>\n<li><strong>Bajo la direcci\u00f3n anterior, la empresa alcanz\u00f3 la fase cl\u00ednica en menos de tres a\u00f1os y reforz\u00f3 su cartera de productos con nuevos programas contra tumores s\u00f3lidos y hematol\u00f3gicos.<\/strong><\/li>\n<\/ul>\n<p>M\u00e1s <a href=\"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/NdP-OneChain-Immunotherapeutics-anuncia-el-nombramiento-su-nuevo-CEO.pdf\" target=\"_blank\" rel=\"noopener\">info<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El Dr. Theoharis ha ocupado puestos clave en varias empresas biotecnol\u00f3gicas y farmac\u00e9uticas de renombre y aporta m\u00e1s de veinte a\u00f1os de experiencia en el campo de la terapia celular y g\u00e9nica, el desarrollo empresarial y la gesti\u00f3n de programas. Se incorpora a la empresa para dirigirla hacia su siguiente fase de crecimiento, forjando nuevas<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[501],"tags":[],"class_list":["post-2988","post","type-post","status-publish","format-standard","hentry","category-noticias"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"El Dr. Theoharis ha ocupado puestos clave en varias empresas biotecnol\u00f3gicas y farmac\u00e9uticas de renombre y aporta m\u00e1s de veinte a\u00f1os de experiencia en el campo de la terapia celular y g\u00e9nica, el desarrollo empresarial y la gesti\u00f3n de programas. Se incorpora a la empresa para dirigirla hacia su siguiente fase de crecimiento, forjando nuevas\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-01T16:18:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-01T16:19:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-228x300.jpeg\" \/>\n<meta name=\"author\" content=\"Bego\u00f1a Aguirre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bego\u00f1a Aguirre\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/\"},\"author\":{\"name\":\"Bego\u00f1a Aguirre\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\"},\"headline\":\"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO\",\"datePublished\":\"2024-02-01T16:18:09+00:00\",\"dateModified\":\"2024-02-01T16:19:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/\"},\"wordCount\":129,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/\",\"url\":\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/\",\"name\":\"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2024-02-01T16:18:09+00:00\",\"dateModified\":\"2024-02-01T16:19:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\",\"name\":\"Bego\u00f1a Aguirre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"caption\":\"Bego\u00f1a Aguirre\"},\"url\":\"https:\/\/invivo.partners\/es\/author\/bego\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/","og_locale":"es_ES","og_type":"article","og_title":"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO - Invivo Partners","og_description":"El Dr. Theoharis ha ocupado puestos clave en varias empresas biotecnol\u00f3gicas y farmac\u00e9uticas de renombre y aporta m\u00e1s de veinte a\u00f1os de experiencia en el campo de la terapia celular y g\u00e9nica, el desarrollo empresarial y la gesti\u00f3n de programas. Se incorpora a la empresa para dirigirla hacia su siguiente fase de crecimiento, forjando nuevas","og_url":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/","og_site_name":"Invivo Partners","article_published_time":"2024-02-01T16:18:09+00:00","article_modified_time":"2024-02-01T16:19:22+00:00","og_image":[{"url":"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/02\/IMG_6507-scaled-e1706803656843-228x300.jpeg"}],"author":"Bego\u00f1a Aguirre","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Bego\u00f1a Aguirre","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/"},"author":{"name":"Bego\u00f1a Aguirre","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee"},"headline":"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO","datePublished":"2024-02-01T16:18:09+00:00","dateModified":"2024-02-01T16:19:22+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/"},"wordCount":129,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/","url":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/","name":"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2024-02-01T16:18:09+00:00","dateModified":"2024-02-01T16:19:22+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/es\/2024\/02\/01\/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/es\/"},{"@type":"ListItem","position":2,"name":"OneChain Immunotherapeutics anuncia el nombramiento del Dr. Stefanos Theoharis como nuevo CEO"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee","name":"Bego\u00f1a Aguirre","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","caption":"Bego\u00f1a Aguirre"},"url":"https:\/\/invivo.partners\/es\/author\/bego\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/posts\/2988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/comments?post=2988"}],"version-history":[{"count":3,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/posts\/2988\/revisions"}],"predecessor-version":[{"id":3001,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/posts\/2988\/revisions\/3001"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/media?parent=2988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/categories?post=2988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/tags?post=2988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}